Volume 22, Issue 2 (6-2019)                   J Arak Uni Med Sci 2019, 22(2): 84-95 | Back to browse issues page

XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Kavousi M, Rahimi E, Fallah Mehrabadi J. The Effect of Cisplatin and Eucalyptus Extract on KRAS Gene Expression in A549 Cell Line of Lung Cancer. J Arak Uni Med Sci 2019; 22 (2) :84-95
URL: http://jams.arakmu.ac.ir/article-1-5970-en.html
1- Department of Biology, East Tehran Branch, Islamic Azad University,Tehran, Iran. , mkavoosi@iauet.ac.ir
2- Department of Biology, East Tehran Branch, Islamic Azad University,Tehran, Iran.
3- Lister Laboratory of Microbiology, Tehran, Iran.
Abstract:   (3934 Views)
Background and Aim: Lung cancer is one of the most contagious cancers in all of the world. Recently, several potential oncogenes and carcinogens have been identified, including EGFR, BRAF, KRAS and ALK genes. With due attention to the high prevalence of lung cancer, its death rate, the complications of chemotherapy and the efforts to find effective and less effective drugs, this study was done to investigate the effect of a plant extract so that results are available to manufacturing centers.
Materials and Methods: In this study, the effect of Eucalyptus extract and cisplatin on the expression of KRAS gene in A549 lung cancer cell line was investigated. To determine the cell survival, MTT was used and IC50 was determined. After determining IC50, the cells were exposed to less than IC50 concentrations of the extract and drug for 48 hours. Then, the amount of β-ACTIN and KRAS genes expressions in control and extract treated and drug treated groups were determined. For this purpose, a specific primers were designed for β- ACTIN and KRAS, and Real-Time PCR was be done.
Ethical Considerations: This study with research ethics code IR.IAU.East Tehran.REC.1396.3 has been approved by research ethics committee at Islamic Azad University, Tehran- East Branch, Iran.
Findings: The results showed that the amount of IC50 of the extract and drug was 8.75 and 1.77 mg/ml, respectively. In addition, the expression of genes in control and treated cells with extract and drug was compared. The expression of the KRAS gene relative to the reference gene in the cancer cell line treated with extract and drug, for 48 hours, was significantly decreased 2.89 and 9.25, respectively (p = 0).
Conclusion: Regarding the reduction of the relative gene expression in the A549 treated group, future studies on targeted lung cancer treatment can be promising and the potential for the use of plant compounds is more evident.
Full-Text [PDF 697 kb]   (1842 Downloads)    
Type of Study: Original Atricle | Subject: Basic Sciences
Received: 2018/12/9 | Accepted: 2019/04/20

References
1. Von Dincklage JJ, Ball D, Silvestri GA. A review of clinical practice guideline for lung cancer. Journal of Thoracic Disease. 2013; 5(suppl 5): S607-S622.
2. Zappa C, Mousa SA. Non-small cell lung cancer: current treatment and future advances. Translational lung cancer research. 2016; 5(3): 288-300.
3. Cooper WA, Lam DC, O’toole SA, Minna JD. Molecular biology of lung cancer. J Thorac Dis. 2013; 5 (suppl 5): S479- S490.
4. Chan BA, Hughes BGM. Targeted therapy for non-small lung cancer: current standards and the promise of the future. Transl Lung Cancer Res. 2015; 4(1): 36-54.
5. Su Y, Hu Y, Wang Y, Xu X. A precision-guided MWNT mediated reawakening the sunk synergy in RAS for anti- angiogenesis lung cancer therapy. Biomaterials. 2017; 139: 75-90.
6. Tomassini P, Walia P, Labbe C, Jao K, Leighl NB. Targeting the KRAS Pathway in Non-Small Cell Lung Cancer. The oncologist. 2016; 21: 1450-1460.
7. D’antonio Ch, Milano A, Righini R, Onesti CE. Pharmacogenomics in Lung Cancer Chemotherapy: A Review of What the Oncologist Should Know. Anticancer Res. 2014; 34: 5241-5250.
8. Mukherjea D, Rybak LP. Pharmacogenomics of cisplatin-induced ototoxicity. Pharmacogenomics. 2011; 12(7): 1039–1050.
9. Boland DJ, Brooker MIH, Chippendale GM, Donald MC, Maurice W, Bradbury PA, Kulke MH, Heist RS, Zhou W. Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes. Pharmacogenet Genomics. 2009; 19(8): 613–625.
10. Rose MC, Kostyanovskaya E, Huang RS. Pharmacogenomics of Cisplatin Sensitivity in Non-small Cell Lung Cancer. Genomics Proteomics Bioinformatics. 2014; 12: 198–209.
11. Cardenas ME, Cruz MC, Del Poeta M, Chung N, Perfect JR, Heitman J . Antifungal activities of antineoplastic agents: Saccharomyces cerevisiae as a model system to study drug action. Clin.Microbiol. Rev. 1999; 12: 583–611.
12. Cragg Gordon M, Newman A, David J. Plants as a source of anti-cancer agents. Journal of Ethnopharmacology. 2005; 100 (1–2): 72–9.
13. Islam F, Khatun H, Khatun M , Mohsin Ali ShM, Khanam JA. Growth inhibition and apoptosis of Ehrlich ascites carcinoma cells by the methanol extract of Eucalyptus camaldulensis .Pharm Biol. 2014; 52(3): 281–290.
14. Ashour HM. Antibacterial, antifungal and anticancer activities of volatile oils and extracts from stems, leaves and flowers of Eucalyptus sideroxylon and Eucalyptus torquata. Cancer Biology and Therapy. 2008; 22(17): 399-403.
15. Gautam N, Mantha A, Mittal S. Essential oils and their constituents as anticancer agents: a mechanistic view. BioMed Research International. 2014; Article ID 154106.
16. Patr´ıcia M, D¨oll-Boscardin, Sartoratto A. In Vitro Cytotoxic Potential of Essential Oils of Eucalyptus benthamii and Its Related Terpenes on Tumor Cell Line. 2012; Article ID 342652.
17. Islam F, Khatun H, Ghosh S , Ali MM, Khanam JA. Bioassay of Eucalyptus extracts for anticancer activity against Ehrlich ascites carcinoma (EAS) cells in Swiss albino mice. Asian Pac J Trop Biomed. 2012; 2(5): 394-39.
18. Caiola E, Salles D, Frapolli R, Lupi M, Rotella G, Ronchi A, Garassino MC, Mattschas N, Colavecchio S, Broggini M, Wiesmuller L, Marabese M. Base excision repair- mediated resistance to cisplatin in KRAS (G12C) mutant NSCLC cells. Oncotarget. 2015; 6(30): 30072-30087.
19. Yong L, Wang P, Li XH, Wang HJ, Sji GN. microRNA-375 confers cisplatin resistance by regulating KRAS expression in non- small cell lung cancer cell. Int J Clin Exp Pathol. 2016; 9(3): 3286-3294.
20. Ranga RS, Sowmyalakshmi S, Burikhanov R, Akbarsha MA, Chendil D. A herbal medicine for the treatment of lung cancer. Mol Med Biochem. 2005; 280(1-2): 125-33.

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Journal of Arak University of Medical Sciences

Designed & Developed by : Yektaweb